NCT04672551Recruiting
EMDR Treatment in PTSD Following Cardiac Events
Source: ClinicalTrials.gov · Last updated 7 May 2026
Brief summary (registry, in English)
Cardiac events can often result in debilitating and persistent psychological symptoms. A key question involves whether optimal treatment of cardiac-induced posttraumatic stress disorder (PTSD) reduces PTSD symptoms and thereby may offset the risk of recurrent or worsening cardiovascular disease. Cardiac-induced PTSD 1) is prevalent, 2) features symptoms unique to internal ongoing somatic threat, with fears and worries that can be distinguished from PTSD resulting from external causes, 3) is persistent, 4) is associated with negative physical and emotional consequences, and 5) has not been the subject of randomized-controlled treatment trials (RCT). There is preliminary evidence suggesting that patients with cardiac-disease induced PTSD might particularly profit from EMDR. Nevertheless, this possibility has not been tested in cardiac-induced PTSD. Currently, patients with cardiac-induced PTSD are not routinely offered trauma-focused therapies, with a lack of scientific evidence likely being one major reason for this omission. If our proposed RCT shows that EMDR can be an effective treatment for patients with ACS-induced PTSD, EMDR could be routinely implemented as first-line treatment. The RCT outcomes might inform larger trials to test whether poor prognosis in terms of major adverse cardiovascular events can be improved through EMDR in patients with cardiac-induced PTSD.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 19 Apr 2020
- Start date
- 21 Nov 2020
- Primary completion date
- 30 Nov 2027
- Lead sponsor
- University of Zurich
- Diseases
- Coronary artery disease
- NCT number
- NCT04672551
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 21 Nov 2020 to the primary completion date, 30 Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Regular medication with benzodiazepine
Other illness
- Psychotic disorder, bipolar disorder, substance abuse as measured with the Mini International Neuropsychiatric Interview (M.I.N.I)
- Ongoing psychological/psychiatric treatment outside of the trial during the study period
Other
- Acute suicidal ideation as assessed with the M.I.N.I.
- Non-selective beta blockers (e.g., propranolol) during the study period
- Visionary problems, e.g. strabismus, which does not allow adequate eye movements
- Insufficient knowledge of the German language
- Expected inability or willingness to follow the study protocol
Who the study is looking for
- Age between 18-70 years
- Men or women
- STEMI (irrespective of troponin, but ST-elevation) or non-STEMI (troponin positive) at the time of the cardiac event, as verified by the cardiologist
- Diagnosis of PTSD caused by the cardiac event
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Zurich Coordinator of this site? Confirm its status | Zurich | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.